Spots Global Cancer Trial Database for Subcutaneous Cardiac Monitoring of Patients With BTK Inhibitors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Subcutaneous Cardiac Monitoring of Patients With BTK Inhibitors

Official Title: Electrocardiographic Changes and Rhythm Disorders Associated With BTK Inhibitors Exposure Using an Insertable Subcutaneous Cardiac Monitor: a Multicenter Cardio-Oncology Prospective Cohort

Study ID: NCT06029166

Conditions

Atrial Fibrillation

Interventions

Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®)

Study Description

Brief Summary: The goal of this clinical trial is to screen all types of electrocardiographic changes and rhythm disorders in adult patients with a hematologic malignancy requiring a treatment by Bruton's tyrosine kinase (BTK) inhibitor (ibrutinib, acalabrutinib, zanubrutinib) using an insertable subcutaneous cardiac monitor (ISCM) and occurring from inclusion and within 12 months. This study consists of the implantation of an ISCM at inclusion and before BTK inhibitor initiation. Then patients will have medical visits every 3 months (+/- 7 days) during 12 months and a continuous cardiac telemonitoring using the ISCM.

Detailed Description: